Bcl-2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-56098
Key Product Details
Validated by
Knockout/Knockdown, Biological Validation
Species Reactivity
Validated:
Human, Mouse, Rat, Canine
Cited:
Human, Mouse, Rat, Canine
Predicted:
Bovine (93%), Feline (100%), Porcine (100%). Backed by our 100% Guarantee.
Applications
Validated:
Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot
Cited:
Block/Neutralize, IF/IHC, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Product Specifications
Immunogen
A synthetic peptide corresponding to amino acids 41-54 (GAAPAPGIFSSQPG) of human Bcl-2 was used as immunogen; GenBank no. NP_000648.2. This sequence is 100% conserved in human Bcl-2 alpha (239 aa) and beta (205 aa) isoforms.
Reactivity Notes
Use in Rat reported in scientific literature (PMID:34575863). Mouse, Canine, Rat reactivity reported in scientific literature (PMID: 15380478).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for Bcl-2 Antibody
Western Blot: Bcl-2 Antibody [NB100-56098]
Western Blot: Bcl-2 Antibody [NB100-56098] - EA reduced MPP+-induced dopaminergic neuronal apoptosis by increasing BDNF (brain-derived neurotrophic factor) expression and further Akt phosphorylation in the rat substantia nigra. Eight days after MPP+ administration, our Western blot results (MAB7566) show that MPP+ treatment reduced tyrosine hydroxylase and Bcl-2 expression in the ipsilateral side of the rat substantia nigra (SN), but not in the contralateral side. EA stimulation (50 Hz) enhanced mature BDNF, tyrosine hydroxylase, and Bcl-2 expression in the MPP+-treated ipsilateral side. Image collected and cropped by CiteAb from the following publication (https://www.mdpi.com/1422-0067/18/9/1846), licensed under a CC-BY license.Immunohistochemistry-Paraffin: Bcl-2 Antibody [NB100-56098]
Immunohistochemistry-Paraffin: Bcl-2 Antibody [NB100-56098] - Analysis of a FFPE human breast carcinoma tissue section using 1:1000 dilution of Bcl-2 antibody (NB100-56098) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of BCL2 in the cancer cells with relatively intense signal in their nuclear membranes. Staining was performed by Histowiz.Applications for Bcl-2 Antibody
Application
Recommended Usage
Immunohistochemistry-Paraffin
1:1000-1:5000
Immunoprecipitation
1:50-1:200
Western Blot
1:1000-1:2000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 3 reviews rated 5 using NB100-56098 in the following applications:
Formulation, Preparation, and Storage
Purification
Unpurified
Formulation
Whole antisera
Preservative
0.05% Sodium Azide
Concentration
This product is unpurified. The exact concentration of antibody is not quantifiable.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Bcl-2
Long Name
B Cell Lymphoma/Leukemia 2
Alternate Names
Bcl2
Entrez Gene IDs
596 (Human)
Gene Symbol
BCL2
Additional Bcl-2 Products
Product Documents for Bcl-2 Antibody
Product Specific Notices for Bcl-2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...